# Market Re-validation 2026-05 — Multi-Model Review Log

**Document under review**: `docs/01-strategy/market-revalidation-2026-05.md` (v1.0)
**Subordinate edits under review**: §13 in `hr-domain-addendum.md`, §12 in `crypto-domain-addendum.md`
**Lead author**: Claude Opus 4.7 (1M context)
**Lead-author session date**: 2026-05-07

---

## Purpose

This file logs the multi-model review rounds applied to the Market Re-validation 2026-05 deliverable. Per the project's stored feedback (`feedback_multi_model_sign_off.md`): multi-model reviews the **final written doc**, not just intermediate decisions. Per `feedback_honest_reviewer_attribution.md`: only models actually invoked in this session are recorded as reviewers — no padding, no fabrication, no re-attribution to a model that wasn't called.

---

## Round 0 — Lead-author drafting (this session)

### Models invoked during Step 1 premise audit (own-knowledge baseline)

| Tool / model | Method | Outcome |
|---|---|---|
| Codex CLI (default role) | `mcp__pal__clink`, single call, 74.9s, 3,602 output tokens | Returned per-claim verdicts on 20 HR + Crypto claims + top-3 evidence picks |
| Gemini 2.5 Pro | `mcp__pal__chat`, thinking_mode=high, single call | Returned per-claim verdicts on identical claim set + top-3 evidence picks |
| `gemini-3-pro-preview` | `mcp__pal__chat` | First-attempt returned 503 UNAVAILABLE; fell back to 2.5 Pro rather than retry-loop a temporarily-unavailable preview model. Honestly recorded — not re-attributed to 3-pro |

### Subagents invoked during Step 2 deep-research

| Subagent | Thread | Outcome |
|---|---|---|
| `deep-research-worker` (T1) | BPO/outsourcing-agency layoff wave | First inline return abbreviated (worker wrote findings to its own memory but did not return them in the inline message); `reference_bpo_outsourcing_sources.md` saved to agent memory; required cross-validation pass to recover findings |
| `deep-research-worker` (T2) | HR-tech market shifts Jan–May 2026 | Full report inline; 28 cited findings across 4 sub-questions |
| `deep-research-worker` (T3) | Crypto market state Q1–Q2 2026 | Full report inline; 18+ cited findings across 5 sub-questions; explicit contradiction flagged on USDT MiCA-license status |
| `deep-research-worker` (T4) | Adjacent niche scan | Full report inline; 21 cited findings; ranked-niche matrix already produced by worker |

### Cross-validation pass

| Tool / model | Method | Outcome |
|---|---|---|
| Codex CLI with web-search | `mcp__pal__clink`, default role, 387.9s, 10,233 output tokens | Re-ran T1 with focused queries to (a) recover the missing inline findings AND (b) independently corroborate the most decision-critical thread. The plan explicitly anticipated this cross-validation step on T1 |

---

## Round 1 — Multi-model review of the written deliverable (PENDING)

**Status**: Round 1 has not yet been executed at the time this skeleton is written. The written deliverable will be sent to Codex (via `mcp__pal__clink`) and Gemini (via `mcp__pal__chat` with `gemini-3-pro-preview` first, fall back to `2.5-pro` if 503) for independent review.

**Review questions (identical to both models)**:
1. Are any §3 (HR) or §4 (Crypto) audit-table verdicts mis-attributed to your earlier audit response? (Honesty check — would catch any drift between the audit reply and the verdict-table summary.)
2. Are any cited findings in §3, §4, or §5 misquoted, mis-dated, or referenced to the wrong source?
3. Are the niche fit-scores in §5 internally consistent given the cited evidence and the published rubric weights?
4. Does §6 over-recommend, under-recommend, or fail to surface a genuinely better option?
5. Are any disputed findings (Section 3.4, 4.4) flattened into false certainty elsewhere in the document?
6. What is missing — niches not surfaced, evidence categories not pulled, premises not audited?

**R1 results**: to be appended below after the round runs.

### R1 — Codex (via `mcp__pal__clink`, role=codereviewer)

**Invocation**: 2026-05-07. 166.8s, 7,920 output tokens. Continuation_id `9bdb2326-613d-4150-b03d-e98111d4d624`.

| Q | Verdict | Specific defect (if any) |
|---|---|---|
| 1 — Verdict-table fidelity | CORRECTION NEEDED | Step-1 Codex verdict artifact not preserved alongside the deliverable; cannot be independently re-audited from the repo alone. |
| 2 — Source/date accuracy | CORRECTION NEEDED | (a) Mobley paragraph cites `[T2-6, T2-7, T2-12]` but T2-6/T2-7 are Phenom/Workday-acquisition refs and T2-12 is FairNow secondary, not a Workday filing pinpoint. (b) EU AI Act paragraph cites `[T2-11, T2-12, T2-13, T2-17]` — T2-11/T2-12 are Workday-related and T2-13 doesn't exist. |
| 3 — Niche scoring consistency | CORRECTION NEEDED | Math is correct (Healthcare 91, Stablecoin 89). Evidence scaffolding broken: Healthcare cites `[T4-8]` for AMA survey but T4-8 in §7 is finance-close material; Legal cites missing `[T4-3]`; Insurance cites missing `[T4-19]`. |
| 4 — Recommendation quality | PASS | Healthcare remains top-ranked; Stablecoin → Healthcare framed as option, not directive. No clearly-better omitted niche found. |
| 5 — Disputed-finding handling | PASS | §6 does not collapse C1 or C6; explicit "verify USDT MiCA status" note is correct restraint. |
| 6 — Honesty audit on attribution | PASS | §8 distinguishes 2.5-Pro from unavailable 3-Pro-Preview; no fabricated reviewer naming. (Caveat: Q1's archival gap independently weakens the Step-1 fidelity claim.) |

**Codex's positive callouts** (preserve in future revisions): the explicit DISPUTED sections (§3.4, §4.4); the option-based recommendation framing in §6.

### R1 — Gemini 3 Pro Preview (via `mcp__pal__chat`, thinking_mode=high)

**Invocation**: 2026-05-07. Continuation_id `426f90c0-aaf3-4a1b-9b22-e12a3f1d1708`. Single call (gemini-3-pro-preview was available for R1 even though it was 503 for Step 1; documented honestly).

| Q | Verdict | Specific defect (if any) |
|---|---|---|
| 1 — Verdict-table fidelity | CORRECTION NEEDED | H6 column shows Gemini 2.5 Pro returned STILL TRUE; Gemini 3 Pro disputes that 2.5 should have returned STILL TRUE for "consent as sole lawful basis." See note below. |
| 2 — Source/date accuracy | CORRECTION NEEDED | (a) Mobley line 103: `[T2-6, T2-7, T2-12]` should be `[T2-9, T2-10, T2-12]`. (b) NPC Advisory line 105: `[T2-14, T2-21]` — T2-14 missing from §7; should be `[T2-20, T2-21]`. |
| 3 — Niche scoring consistency | PASS | (Gemini 3 Pro did not flag the §5 broken cites that Codex caught — Codex caught more here.) |
| 4 — Recommendation quality | CORRECTION NEEDED | Over-recommends Stablecoin/PPSI as "low-cost validator." Validating against an open NPRM (comments don't close until 2026-06-09) risks wasted engineering if final rules shift. Recommends sequencing Healthcare PA first as its CMS-0057-F mandate is already live. |
| 5 — Disputed-finding handling | CORRECTION NEEDED | §6.2 lists 5 doc updates from §4.3 but quietly drops the C1 time-savings qualification — which is in §4.1 and §4.4 but not in §4.3's numbered list. |
| 6 — Honesty audit on attribution | PASS | No fabricated attribution. |

**Note on Gemini 3 Pro's H6 dispute** — the deliverable preserves the literal verdict that Gemini 2.5 Pro returned in Step 1 (continuation_id `962ea320-d183-4083-9ede-3b5c3c2e7730`, response timestamp 2026-05-07): "H6 | `STILL TRUE` | The specified data retention periods align with common regulatory practices for tax, labor, and data privacy as of Jan 2026." Gemini 3 Pro's R1 critique is a model-self-second-guess, not a fabrication catch. The remediation is to record this disagreement transparently (now done in §3.4), not to retro-edit 2.5's verdict.

---

## Round 1 corrections applied (2026-05-07)

The following edits were made to `market-revalidation-2026-05.md` after R1:

1. **§3.2 Mobley paragraph** — citations corrected from `[T2-6, T2-7, T2-12]` to `[T2-9, T2-10]` (class certification + customer-list discovery), `[T2-11]` (HR Dive customer-list order), and `[T2-12]` (FairNow analysis of 1.1B figure, with explicit "secondary analysis, not a filing pinpoint" qualifier).
2. **§3.2 EU AI Act paragraph** — citations corrected from `[T2-11, T2-12, T2-13, T2-17]` to `[T2-17, T2-18]` (TechPolicy.Press, IAPP, DLA Piper).
3. **§3.2 NPC Advisory paragraph** — citations corrected from `[T2-14, T2-21]` to `[T2-20, T2-21]` (Securiti, L&E Global).
4. **§5.2 Healthcare AMA citation** — corrected from `[T4-8]` (which is finance-close) to `[T4-5]` (Kansas Legislative Research briefing book, which compiles the AMA survey alongside state-law list). CMS-0057-F also cited explicitly as `[T4-4]`.
5. **§5.2 Legal mid-market inference** — broken `[T4-3]` removed and replaced with explicit "(inference from Harvey enterprise-customer composition; not a direct market-segmentation cite)" — matches the actual provenance.
6. **§5.2 Insurance citation** — corrected from `[T4-19]` to `[T4-6]` (Enlyte, which has the FL/AZ/CO/NAIC content).
7. **§2.1 added "verdict-table fidelity note"** — names the continuation_ids for both Step-1 audit calls so future readers can locate the raw responses.
8. **§6.2 added explicit C1 qualification action** as a numbered item, ensuring the disputed-finding qualification is not lost when the addendum is edited.
9. **§6.3 sequencing — added DISPUTED tag** with both options (A/B) explicit, surfacing R1 reviewer split without flattening.
10. **§3.4 added H6 disagreement note** — records the verdict split without retro-editing the original Step-1 verdicts.

## R2 — not invoked on the v1 deliverable

R1 surfaced citation-integrity defects and recommendation-framing improvements, both correctable inline without changing any verdict. No disputed claim survived R1 in a way that would change a domain verdict (HR or Crypto) or top-2 niche ranking. R2 is not required.

## Post-R1 decision dispatch — Agency-track TTFR ranking (2026-05-07)

After the operator added a binding constraint ("ROI-speed = time-to-first-revenue, not TAM"), a follow-up multi-model query was dispatched to rank three agency-track options under the new criterion. This is NOT a review of the deliverable — it is a decision-support call that the deliverable has been amended to record (§6.5).

### Codex (via `mcp__pal__clink`, role=default)

- **Invocation**: 2026-05-07. 58.0s, 2,736 output tokens. Continuation_id `0fcd0663-25fb-48a9-98df-e34163df1523`.
- **Ranking**: C > B > A.
- **TTFC estimates**: C 0.5–2mo / B 3–6mo / A 9–15mo.
- **Time to $5K MRR**: C 1–3mo / B 6–9mo / A 12–18mo.
- **Sequencing**: pursue C alone for 30 days; if C fails, fall back to B (NOT A); A is too slow + cert-heavy for self-funded constraint regardless.

### Gemini 3 Pro Preview (via `mcp__pal__chat`, thinking_mode=high)

- **Invocation**: 2026-05-07. Continuation_id `29f2f1f4-7a6d-405b-820b-2b3be3b0e0e8`.
- **Ranking**: C > B > A.
- **TTFC estimates**: C 1–2mo / B 4–6mo / A 9–12mo.
- **Time to $5K MRR**: C 2–3mo / B 6–9mo / A 12–18mo.
- **Sequencing**: pursue C alone first; if C succeeds, use cash-flow to fund A's HIPAA/HITRUST/SOC2 cert workstream and pursue A as long-term wedge. **Discard B** as distraction with strong incumbent gravity (Harvey).
- **Fail-fast specifics**: "Shadow Audit & SLA Upsell" — 3 existing clients run through Aptivo in shadow mode → Vendor-AI Liability Audit → 30% pricing-premium pitch → 30-day gate (2 paid upgrades or 1 client at $1.5K+ MRR).

### Synthesis (recorded in §6.5 of the deliverable)

Convergent on the answer (C > B > A) and on the immediate action (C alone first; not parallel). Divergent on the fallback/succession leg only — Codex addresses C-failure (→ B), Gemini addresses C-success (→ A). Both are non-contradictory; both retained in the adopted decision. Discard-B (Gemini-only) is NOT adopted in §6.5 — Codex's argument that B is the cleanest C-failure fallback is preserved.

### Honest-attribution note

This decision dispatch is a separate session-event from the R1 review of the written deliverable (logged above). It is recorded here for traceability rather than rolled into R1, because the question is materially different ("rank under TTFR") from the R1 questions ("are the docs accurate?").

## Post-disclosure decision dispatch — Re-rank with corrected ground truth (2026-05-07)

After the §6.5 decision was recorded, the operator disclosed material context that invalidated the Option-C premise: no existing agency clients (HR was speculative); team expertise is GHL agency ops + RE/business-brokerage VAs (not HR-recruiting); team includes one dermatologist (relevant to healthcare A'). A second decision dispatch was run with the corrected reality.

### Codex (via `mcp__pal__clink`, role=default)

- **Invocation**: 2026-05-07. 49.4s, 2,274 output tokens. Continuation_id `7a9b0d4b-23a1-46b1-825e-d3cd3bc9f8aa`.
- **Ranking**: G > D > A' > B > HR-rebuild.
- **TTFR estimates**: G 1–2mo / 2–4mo; D 2–4mo / 4–7mo.
- **Explicitly stated**: "Prior `C > B > A` ranking is wrong under the corrected ground truth. It depended on an assumed existing client base that does not exist."
- **On dermatologist asymmetry**: "moves A from 'too slow for a self-funded first wedge' to 'credible later wedge.' But HIPAA, clinical-risk tolerance, workflow integration, and physician trust still make it slower than G and probably slower than D."
- **On HR**: "retire as a commercialization thesis. Keep the domain addendum only as internal product history / reusable workflow patterns. Do not spend cycles trying to rescue an HR go-to-market that was speculative."

### Gemini 3 Pro Preview (via `mcp__pal__chat`, thinking_mode=high)

- **Invocation**: 2026-05-07. Continuation_id `24baa427-7764-451a-a76e-2ac430e712cf`.
- **Ranking**: G > D > A' > B > HR-rebuild.
- **TTFR estimates**: G 0.5–1.5mo / 2–3mo; D 1–2.5mo / 4–6mo.
- **Explicitly stated**: "My prior C > B > A ranking is dead and entirely invalidated. If there are no existing agency clients, Option C (pivot existing clients) is a hallucination."
- **Pricing model**: $199–$299/mo per sub-account or agency tier; $200+/mo paid-tier conversion gate.
- **Fail-fast specifics**: "Rogue AI Overspend & TCPA Gate Sprint" — webhook hook in week 1, distribution via r/GoHighLevel + private GHL FB groups in week 2, 3 beta agencies onboarded weeks 3–4, 14-day shadow → paid-tier gate.
- **On dermatologist asymmetry**: "Be honest: No, it does not meaningfully change the TTFR... It takes A' from 'impossible' to 'highly defensible,' but it remains a 6–12 month TTFR path. You cannot self-fund that burn without a bridge. Option G is the bridge."
- **On HR**: "Retire it completely. Strip the HR addendum from active development focus. Keep the underlying Inngest + HITL platform primitives, but completely discard the HR/Recruiting go-to-market narrative."

### Synthesis (recorded in §6.6 of the deliverable)

- **Convergent ranking**: G > D > A' > B > HR-rebuild (no dissent).
- **Convergent fail-fast shape**: build narrow webhook-routed Aptivo HITL gate for GHL outbound AI-generated SMS/email; distribute via GHL communities; gate on paid pilots within 30 days.
- **Convergent sequencing**: G alone first (no parallel); if G succeeds → fund A' from cash flow; if G fails → pivot to D; B and HR-rebuild dropped.
- **Stronger-than-prior-round commitment**: both reviewers explicitly stated their own prior-round answer was wrong under corrected reality. This is the right pattern — admit invalidation, don't anchor.

### Honest disclaimers added to §6.6

- Reviewers have zero buyer-network in G/D/A'/B niches — they ranked on structural fit, not warm-intro access.
- TTFR estimates are within-model best-guess, not historical-data anchored.
- §6.6 supersedes §6.5; both kept in document for diff readability.

## Round 3 — Research-validated stress-test (2026-05-07)

After the §6.6 decision, the operator pushed back with three sharp questions:
1. Are we tunnel-visioning into GHL? Do we have a USP, or are we competing with GHL's own roadmap?
2. Is there an angle/sub-niche our platform shines in AND that's underserved (proven by research/sentiment, not asserted)?
3. Are the GHL compliance pains and "speculative HR" claims backed by research?

Three `deep-research-worker` subagents dispatched in parallel:

### RT1 — GHL roadmap + agency-pain reality check

- **Worker**: `deep-research-worker` agent ID `a2e50196d2d7ddbcf`. Memory artifact at `~/.claude/agent-memory/deep-research-worker/reference_ghl_*` (per worker convention).
- **Verdict**: G thesis as positioned should be **REJECTED**. GHL has shipped most of the overlay surface natively (Voice AI compliance gates, Conversation AI Suggestive Mode, Reviews AI human-approve, native audit logs, HIPAA add-on, SB-140 safeguard). Loudest agency pain is utility-shaped (better AI answers, longer audit retention, API export), not governance-shaped (approval gates).
- **Existing competitor surfaced**: SuperAuditor occupies the cost-visibility slot.
- **Recommended remediation**: 8-12 direct GHL-agency interviews before committing 2-4 weeks.

### RT2 — Underserved SMB-automation sub-niches

- **Worker**: `deep-research-worker` agent ID `a4c7083c8033bd1d9`. Memory artifact `reference_smb_automation_pain_sources.md`.
- **Three viable candidates surfaced**:
  - Cold-email deliverability + RFC-8058 compliance gating (Validity 2025 benchmark: 1-in-6 emails miss inbox; pain strongest, vendor field crowded).
  - n8n/Make/Zapier AI cost-governance + audit overlay (Activepieces $30K/yr Embed validates monetization; Cledara survey: "complete blindness" on per-workflow AI costs; Wednesday.is multi-tenancy guide explicit gaps in n8n audit/billing/RBAC/rate-limit). **Team lacks first-person community fit.**
  - AI marketing compliance / TCPA AI-voice (FTC Air AI $18M settlement March 2026 + state laws Jun-Aug 2026; federal enforcement direction partially deregulating, weakens urgency).
- **Discarded**: SMB-tier agent observability (`[unknown — pain inferred, not documented]`).
- **Sourcing gap flagged**: Reddit-direct unreachable; complaints are second-hand via vendor-comparison posts.

### RT3 — RE/brokerage + dermatology-adjacent

- **Worker**: `deep-research-worker` agent ID `ad5e33618312f665f`. Memory artifact `reference_smb_compliance_niche_sources.md`. 33 cited sources.
- **Strongest expert-transition surface**: BRA + transaction-coordinator workflow tooling for solo/small RE brokerages. Documented post-2024-08-17 NAR settlement pain; CA AB 2992 (3-month void rule), CA AB 723 (AI-photo misdemeanor 2026-01-01); 18 NAR MLS policy updates in Jan 2026. Direct VA-team domain match. Lower regulatory burden than healthcare PA.
- **Strong second wedge**: SMB business broker NDA/CIM/buyer-vetting. RBAC+audit+HITL maps 1:1 to broker workflow; thinnest incumbent field at solo tier; lowest regulatory burden.
- **Critical red flag — A' was misread**: cash-pay does NOT exempt MedSpas from HIPAA when handling PHI (multiple authoritative sources unanimous). State regulatory burden INCREASING 2025-2026 (19 states with substantive bills Q1 2025; TX HB 3749/3889/3890; CA criminal penalties for ownership-structure violations). Dermatologist asymmetry real but narrow; only fit avoiding covered-entity status is AI-content-compliance review for MedSpa marketing agencies.
- **Mortgage broker dropped**: CFPB enforcement collapsed 2025 (12 actions, second-fewest in a decade); compliance-buyer persona fragmented to state regulators.
- **Sourcing gap flagged**: Reddit/forum direct quote capture failed via WebSearch.

### Synthesis (recorded in §6.7 of the deliverable)

- **G — REJECTED** by RT1 buyer-evidence. The §6.6 ranking was reviewer-confidence-without-evidence.
- **A' — REJECTED** by RT3 (MedSpa HIPAA framing was wrong).
- **D promoted to #1**: D-RE (BRA + transaction-coordinator workflow) is the strongest research-backed wedge.
- **D-BBK (business broker NDA/CIM)**: new explicit #1b, sister wedge on same platform.
- **A''**: reframed to MedSpa AI-content-compliance for marketing agencies (vendor-to-agency, avoids covered-entity status). Possible third leg post-D revenue.

### Honest disclaimers added to §6.7

- Direct Reddit/FB-group buyer voice was UNREACHABLE in the research (WebSearch/WebFetch 403). All three workers flagged this as the residual sourcing gap. Recommended remediation: founder does in-browser FB-group capture as part of the fail-fast sprint (Lab Coat Agents for RE; IBBA forums for business broker; MedSpa-owner FB groups).
- §6.7 supersedes §6.6 supersedes §6.5. Three rounds, two reversals — pattern logged in §6.7 as cautionary tale on reviewer-confidence-without-buyer-evidence.

## Round 4 — Skill-first stress-test (2026-05-07)

Operator pushed back on §6.7's framing of "GHL expertise vs. n8n expertise" — correctly noting that if the tool is removed, the underlying skill (automation) is the same. Tool-fixation across §6.5/§6.6/§6.7 was hiding skill-derived niches. Re-ran multi-model with skill-first framing + new long-term-niche dimension.

### Codex (via `mcp__pal__clink`, role=default)

- **Invocation**: 2026-05-07. 72.1s, 3,494 output tokens. Continuation_id `4080d721-37b0-4e23-948a-04e3f0d2ebc1`.
- **Verdict**: EXPAND §6.7. Skill-first reframe does NOT overturn D-RE + D-BBK on TTFR; in fact strengthens them.
- **D-BBK ranked #1**: cleanest Aptivo-native fit overall (RBAC + audit + HITL map 1:1 to NDA/CIM/buyer-vetting workflows).
- **Long-term legs**: A'' MedSpa content-compliance for agencies + cross-stack automation governance.
- **On SDR-as-a-Service**: thin-services play; Aptivo is a thin layer over service delivery. Skeptical of platform-wedge framing.

### Gemini 3 Pro Preview (via `mcp__pal__chat`, thinking_mode=high)

- **Invocation**: 2026-05-07. Continuation_id `b4e42e85-7447-42ae-9a11-7761ff692c40`.
- **Verdict**: EXPAND §6.7. D-RE + D-BBK remain undisputed TTFR champions.
- **Long-term legs**: MedSpa Medical SEO + Content Compliance (WP+Derm overlap) as primary long-term; Healthcare PA as moonshot.
- **On SDR-as-a-Service**: STRONG #2 TTFR wedge. Frames it as "auditable SDR-as-a-service" — converts cold-calling team into compliance-augmented outbound infrastructure with TCPA/hallucination HITL gates. Real platform play.

### Synthesis (recorded in §6.8 of the deliverable)

- **Convergent**: §6.7 expand-not-revise; D-RE + D-BBK as Tier 1; MedSpa-derm-content-compliance as long-term; cross-stack automation governance as long-term capability expansion.
- **Divergent**: SDR-as-a-Service classification — Gemini #2 TTFR vs. Codex thin-services. Recorded as DISPUTED Tier 2 in §6.8, resolved by buyer-voice capture in week 1.
- **Tunnel-vision audit**: both reviewers explicitly admitted prior rounds tool-fixated. Codex called out: "GHL expertise was over-identified with the GHL product surface." Gemini called out: "We let the tool dictate the TAM" + WordPress + Cold-calling skills missed.
- **Operator's discipline credited**: four-round stress-test produced order-of-magnitude better answer than any single round.

### Honest-attribution note

§6.8 represents qualitative skill-first reasoning, not new web research. Reviewers reasoned from team-skill inventory + research already in the doc. Tier-2 and Tier-3 buyer-pain validation remains pending direct buyer voice capture during week-1 fail-fast sprint.

---

## Honest-attribution audit (final, before commit)

- [x] Every model named in `market-revalidation-2026-05.md` §8 was actually invoked in this session (Codex × 3 invocations: Step-1 audit, T1 cross-validation, R1 review; Gemini 2.5 Pro × 1 in Step-1 audit; Gemini 3 Pro Preview × 1 in R1 review)
- [x] Every model named in §3 / §4 verdict tables matches the audit responses they actually returned in Step 1 (Codex 49398864-3e83 / Gemini 2.5 962ea320-d183)
- [x] No reviewer named who didn't appear in this session's tool-call log
- [x] H6 disagreement between Gemini 2.5 (Step 1) and Gemini 3 Pro (R1) is recorded as such in §3.4, not flattened
- [x] Subagent-returned findings are cited to their primary sources, not to the subagent itself
- [x] Sequencing dispute between Codex and Gemini 3 Pro recorded in §6.3 as DISPUTED with both options preserved

---

## Round 2 — Targeted re-review (CONDITIONAL)

R2 runs only if R1 surfaces disputed claims that would change a verdict (HR, Crypto, or niche ranking). If R1 surfaces only minor corrections, those are applied to the doc directly without R2.

### R2 results
*(only filled if invoked)*

---

## Honest-attribution audit (final, before commit)

**Checklist**:
- [ ] Every model named anywhere in `market-revalidation-2026-05.md` §8 was actually invoked in this session (Codex × 2 invocations confirmed; Gemini 2.5 Pro × 1 invocation confirmed; gemini-3-pro-preview unavailability documented honestly rather than re-attributed)
- [ ] Every model named in §3 / §4 verdict tables matches the audit responses they actually returned in Round 0
- [ ] No reviewer named who didn't appear in this session's tool-call log
- [ ] Disputes from R1 (if any) are recorded as disputed, not flattened
- [ ] Subagent-returned findings are cited to their primary sources, not to the subagent itself

---

## Notes on prior multi-review precedents

This review follows the same structure as `S17_PLAN_MULTI_REVIEW.md`, `S18_*_MULTI_REVIEW.md`, and the original `APTIVO_STRATEGY_MULTI_REVIEW.md`. The lessons applied here from prior sprints:
- **S18 honesty audit lesson**: pre-commit drafts of delivery-review docs have previously included fabricated reviewer names, ghost shell scripts, and false "Phase 3 wrap" claims. The fix has been to run a multi-model audit on the delivery-review doc itself, not just the underlying code/strategy. This file is structured to make that audit easy.
- **S17 CT-3/CT-4 pattern**: Codex catches state-machine + concurrency defects; Gemini's depth varies by prompt structure. We sent identical prompts to both; we did NOT cherry-pick.
- **S16/S17 plan reviews**: Codex and Gemini's verdicts disagreed on capacity by ~10 SP. We do not synthesize-away disagreement; disputed findings stay disputed.
